<DOC>
	<DOCNO>NCT01766401</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability vilazodone relative placebo treatment generalize anxiety disorder ( GAD ) .</brief_summary>
	<brief_title>Safety , Efficacy Tolerability Vilazodone Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Male female , 18 70 Years age Currently meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion Generalized Anxiety Disorder ( GAD ) Minimum score 20 Hamilton Rating Scale Anxiety ( HAMA ) Women pregnant , woman breastfeed study , woman childbearing potential practicing reliable method birth control Patients history meeting DSMIVTR criterion : manic , hypomanic mixed episode , include bipolar disorder substanceinduced manic , hypomanic , mixed episode ; depressive episode psychotic catatonic feature ; panic disorder without agoraphobia ; obsessivecompulsive disorder ; Schizophrenia , schizoaffective , psychotic disorder ; bulimia anorexia nervosa ; presence borderline personality disorder antisocial personality disorder ; mental retardation , dementia , amnesia , cognitive disorder Patients consider suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>GAD</keyword>
</DOC>